×
About 52,018 results
Opioid Use Disorder: Medical Treatment Options
https://www.aafp.org/afp/2019/1001/p416.html
American Family Physician; Coffa, D. et. al.

Sep 30th, 2019 - Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, pat...

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
https://annals.org/aim/fullarticle/2751913/prevention-diagnosis-evaluation-treatment-hepatitis-c-virus-infection-chronic-kidney

Sep 23rd, 2019 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs...

Alarming number of heart infections tied to opioid epidemic
https://newsroom.heart.org/news/alarming-number-of-heart-infections-tied-to-opioid-epidemic

Sep 17th, 2019 - An alarming number of people nationwide are developing infections of either the heart’s inner lining or valves, known as infective endocarditis, in large part, due to the current opioid epidemic. This new trend predominantly affects young, white, poor men who also have higher rates of HIV, hepatitis C and alcohol abuse, according to new research published in the Journal of the American Heart As...

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and

Aug 27th, 2019 - The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure. All these medicines contain a hepatitis C virus (HCV) protease inhibitor and are not indicated for use in patients with moderate to sever...

Treating Hepatitis C in the Family Medicine Office
https://www.aafp.org/afp/2019/0815/p248.html
American Family Physician;

Aug 14th, 2019 - Patient story about being diagnosed with hepatitis C and successful treatment by family doctor.

HIV and Viral Hepatitis - CDC
https://www.cdc.gov/hiv/pdf/library/factsheets/hiv-viral-hepatitis.pdf

Jun 26th, 2019 - People with HIV infection are affected disproportionally by viral hepatitis. Nearly 75% of people with HIV who report a history of injection drug use also are infected with hepatitis C virus (HCV).

Hepatitis C Questions and Answers for Health Professionals
https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm

Apr 8th, 2019 - What are the case definitions for reportable hepatitis C virus (HCV) infections? The specific viral cause of illness cannot be determined based solely on signs, symptoms, history, or current risk factors, but must be verified by specific serologic testing

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
https://jnccn.org/view/journals/jnccn/17/4/article-p302.xml
Benson, A. et. al.

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C
https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2018.05232?journalCode=hlthaff
Powell, D. et. al.

Feb 3rd, 2019 - The hepatitis C virus is responsible for more deaths in the United States than any other infectious disease, and hepatitis C infections have been rising at an alarming rate since 2010. We evaluated the role of the opioid epidemic and, in particular, the 2010 introduction of an abuse-deterrent version of OxyContin. The OxyContin reformulation led some users of the drug to switch to heroin, which...

Hepatitis, Nonalcoholic Steatohepatitis
https://www.ncbi.nlm.nih.gov/books/NBK470243/
Sharma, B. et. al.

Jan 31st, 2019 - Nonalcoholic, fatty liver disease (NAFLD) is defined as the ectopic accumulation of fat in the liver (hepatic steatosis) when no other causes of secondary, liver fat accumulation are present. As minor deposition of fat can occur in healthy adults, deposition of fat in at least 5% of hepatocytes is considered pathologic. Nonalcoholic steatohepatitis (NASH) is diagnosed via a liver biopsy when th...

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
https://www.gastrojournal.org/article/S0016-5085(19)30057-5/pdf
Singal, A. et. al.

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices
https://jamanetwork.com/journals/jamaoncology/fullarticle/2721238
Ramsey, S. et. al.

Jan 16th, 2019 - Screening patients with newly diagnosed cancer to identify hepatitis B virus and hepatitis C virus infection before starting treatment may be warranted to prevent viral reactivation and adverse clinical outcomes; universal screening for HIV infection may not be warranted.

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Trea...
https://www.aasld.org/sites/default/files/PracticeGuidelines-HCV-November2018.pdf
AASLD-IDSA HCV Guidance Panel

Oct 29th, 2018 - Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommendations. Launched in 2014, the hepatitis C virus (HCV) guidanc.

Hepatitis C - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK430897/

Oct 26th, 2018 - First diagnosed in 1989, hepatitis C virus (HCV) is a major public health problem affecting 185 million people worldwide. The percentage of people who are seropositive for anti-HCV antibodies worldwide is estimated to have increased from 2.3% to 2.8% between 1990 to 2005.

Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus In...
https://www.ncbi.nlm.nih.gov/books/NBK531733/pdf/Bookshelf_NBK531733.pdf
WHO

Jun 30th, 2018 - These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV (Hepatitis C Virus) infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016.

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
https://www.hcvguidelines.org/

May 23rd, 2018 - New direct-acting oral agents capable of curing hepatitis C virus (HCV) infection have been approved for use in the United States. The initial direct-acting agents were approved in 2011, and many more oral drugs are expected to be approved in the next few years.

Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Asso...
https://s3.amazonaws.com/aga-guidelines/pdf/HepCPathway_2017_full+article.pdf
Kanwal F

Apr 30th, 2017 - Chronic hepatitis C virus (HCV) infection is a common condition that affects more than 2. 7 million individuals in the US.

American Gastroenterological Association Institute Clinical Practice Update—Expert Review: C...
https://www.gastrojournal.org/article/S0016-5085(17)30327-X/fulltext?code=ygast-site
Ira M. Jacobson

Apr 30th, 2017 - Chronic hepatitis C virus infection is well-recognized as a common blood-borne infection with global public health impact affecting 3 to 5 million persons in the United States and more than 170 million persons worldwide. Chronic hepatitis C virus infection is associated with significant morbidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma.

Hepatitis C Infection: ASAM Guideline
https://asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2017/04/11/hepatitis-c
American Society of Addiction Medicine

Apr 4th, 2017 - HCV is primarily transmitted through percutaneous exposure to contaminated blood. Since 1992, the US blood supply has been screened for Hepatitis C, making the risk of transfusion-transmitted HCV extremely rare.

WHO Guidelines on Hepatitis B and C Testing
https://www.ncbi.nlm.nih.gov/books/NBK442272/pdf/Bookshelf_NBK442272.pdf
WHO

Feb 15th, 2017 - Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease.